News | Mammography | February 25, 2020

Women 75-plus May Not Benefit from Breast Cancer Screening

Randomized trials have shown that initiating breast cancer screening between ages 50 and 69 years and continuing it for 10 years decreases breast cancer mortality. However, no trials have studied whether or when women can safely stop screening mammography. An estimated 52 percent of women aged 75 years or older undergo screening mammography in the United States.

Women 75-plus May Not Benefit from Breast Cancer Screening

February 25, 2020 — According to newly published research in an article titled Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older Than 70 Years, healthy women over the age of 75 years might not benefit from continuing breast cancer screening. Researchers used data from the Medicare program to estimate the risk of breast cancer mortality under two strategies: continuing versus stopping screening in older women. They found a small mortality benefit for continuing to screen women between the ages of 70 to 74, but not those between 75 to 84. Findings from this population-based observational study are published in Annals of Internal Medicine.

An important question in cancer screening is the age at which it should stop. At some age, the modest potential harms associated with screening will outweigh the benefits because the latter accrue in the future. Researchers from the Harvard T.H. Chan School of Public Health, the Massachusetts General Hospital and RTI Health Solutions used Medicare data to compare deaths from breast cancer over eight years follow-up in women who continued getting yearly mammograms and those who stopped screening. More than one million women between the ages of 70 and 84 years who had a mammography, a life expectancy of at least 10 years, and no previous cancer diagnosis were included in the evaluation. The researchers found that continuing breast cancer screening would reduce 8-year breast cancer mortality by one death per 1,000 women, with the 95 percent confidence interval (CI) ranging from two deaths to none. In contrast, continuing to screen women 75 years or older does not seem to affect 8-year breast cancer mortality. Regardless of age, women were less likely to receive aggressive therapies (radical mastectomy, chemotherapy) for breast cancer if they continued screening.

According to an editorial by Otis Brawley, M.D., from Johns Hopkins University, the study's main disadvantage is that it uses data gathered between 1999 and 2008 when digital mammography was being introduced. It is basically the standard today. One-third of American women who die of breast cancer are diagnosed after age 70. These current estimates of the benefits of screening in this age range also reflect the current breast cancer treatments used in women over 70 potentially more than it does on the limitations of mammography.

For more information: https://www.acponline.org/

 

Related articles on breast imaging for older women:

On Mammography Screening for Women Older Than 70 Years

Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older Than 70 Years

Related Content

Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Getty Images

News | Breast Imaging | July 09, 2020
July 9, 2020 — Chest radiation is used to treat children with Hodgkin and non-Hodgkin lymphoma as well as lung metast
Hologic, Inc. announced he U.S. launch of the SuperSonic MACH 40 ultrasound system, expanding the company’s suite of ultrasound technologies with its first premium, cart-based system.
News | Breast Imaging | July 08, 2020
July 8, 2020 — Hologic, Inc. announced he U.S.
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 30, 2020 | By Melinda Taschetta-Millane
VolparaEnterprise data analysis shows mammography screening volumes are quickly increasing
News | Mammography | June 09, 2020
June 9, 2020 — More than 75 percent of hospitals and imaging centers that perform mammography across the United State
Developed by medical AI company Lunit, Software detects breast cancer with 97% accuracy; Study in Lancet Digital Health shows that Lunit INSIGHT MMG-aided radiologists showed an increase in sensitivity

Lunit INSIGHT MMG

News | Artificial Intelligence | June 02, 2020
June 2, 2020 — Lunit announced that its artificia...
AI has the potential to help radiologists improve the efficiency and effectiveness of breast cancer imaging

Getty Images

Feature | Breast Imaging | May 28, 2020 | By January Lopez, M.D.
Headlines around the world the past several months declared that...
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
Phone call and linkage-to-care-based intervention increases mammography uptake among primary care patients at an urban safety-net hospital

Getty Images

News | Mammography | May 22, 2020
May 22, 2020 — Telephone outreach coupled with scheduling assistance significantly increased...
The Breast Imaging and Reporting System (BI-RADS) was established by the American College of Radiology to help classify findings on mammography. Findings are classified based on the risk of breast cancer, with a BI-RADS 2 lesion being benign, or not cancerous, and BI-RADS 6 representing a lesion that is biopsy-proven to be malignant.

Getty Images

News | Breast Imaging | May 19, 2020
May 19, 2020 — Women with mammographically detected breast lesions that are probably benign should have follow-up sur